Learner1
Senior Member
- Messages
- 6,312
- Location
- Pacific Northwest
These people were looking at the potential to neatly make curcumin into a drug. What they found, as with other natural substances, is that curcumin is a very complex substance with complex interactions with human biochemistry and very difficult to isolate a particular component of curcumin and test its effects so that they can make a drug out of it, but as with other natural substances, unraveling the complexity with out-of-the-box thinking may help future scientists be able to make it into a drug.However, I did happen upon the following review which I found interesting.
I haven't had a chance to read this thoroughly, but it sounds like this is in line what other posts are saying?
Comments?
From the conclusion:
we do not rule out the possibility that an extract of crude turmeric might have beneficial effects on human health.
The large RC of NP extracts, and even of refined NP preparations, makes the identification of the active constituents and
evaluation of their efficacy in humans very
difficult.
Considering the overwhelming evidence showing the weakness of isolated curcumin (almost always a mixture of curcuminoids) as a viable therapeutic, consideration of holistic approaches that take into account the chemical and PD/PK complexity of turmeric and its broad TxM/nutritional foundation appears to be superior directions for future research in the turmeric domain.
While the concepts of static and dynamic RC apply equally to synthetically prepared compounds, the development of leads sourced from metabolomic (natural) sources is intrinsically more prone to the impact of purity (and unknown impurities).
In some ways, the over-simplification of this complexity has led to complicatedness that makes it difficult to interpret results of curcumin-based studies.
In addition, there is increasing evidence that TxM agents cannot be adequately described with reductionist pharmacology models but require consideration of polypharmacology and synergy.
The recent recognition of IMPS4 adds to the uniqueness of natural products by identifying panacea-type substances that establish a new dimension of biological signatures generated by bioactive molecules.
Curcumin is not the only potential IMP that has received much attention by the scientific community as a drug lead. Development projects with numerous other prominent plant
natural products (e.g., polyphenolics) have experienced similar drawbacks despite major efforts.
As shown here for curcumin, the essential medicinal chemistry of natural products that were developed into drugs successfully, and as almost unaltered structures (e.g., artemisinin, camptothecin, taxol, ivermectin, etc.), differs significantly from those of potential IMPS.
This orthogonal perspective on the druggability of NPs is further supported by the metabolic feedback hypothesis, which states that bioactivity, especially of many food-borne phytochemicals, can act via weak negative biological feedback mechanisms, escaping in vitro detection and blurring our
understanding of mechanisms of action.
Collectively, recognition of these factors may remove complicatedness from ongoing research while inspiring the development of out-of-the-box approaches to unraveling the complexity and potential health benefits of turmeric and other NPs.